FDA cites an ‘on­go­ing re­view’ for Pfiz­er's block­buster Xel­janz, with im­pli­ca­tions for the class

On Wednes­day a Pfiz­er rep­re­sen­ta­tive told End­points News that the phar­ma gi­ant had no im­me­di­ate plans to take any new ac­tions re­lat­ed to the mar­ket­ing of their block­buster drug Xel­janz. But it’s not en­tire­ly in their hands.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.